NCT05738382尚未招募2 期
A Randomized, Double-blind, Open for Active Comparator, Parallel, Multi-center Phase II Study to Explore the Efficacy, Safety and Tolerability of BG2109 Compared With Cetrorelix During COH in Female Subjects Undergoing ART Procedures
Bio Genuine (Shanghai) Biotech Co., Ltd.10 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2023年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 240
- 试验地点
- 10
- 主要终点
- Suppression rate of premature LH surge from the treatment of investigational medicinal products(IMP) until the day of human chorionic gonadotropin(hCG) injection
研究概览
简要总结
To explore the optimal effective daily dose of BG2109 to suppress premature luteinizing hormone (LH) surge during COH in female subjects undergoing ART procedures.
详细描述
This study is a randomized, double-blind, open for active comparator, parallel, multi-center phase II dose-finding clinical study to explore the efficacy, safety and tolerability of different doses of BG2109 compared with Cetrorelix during Controlled Ovarian Hyperstimulation (COH) in Chinese female subjects undergoing Assisted Reproductive Technology (ART) procedures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Masked for BG2109 dose groups and open for the active controlled group.
入排标准
- 年龄范围
- 20 Years 至 39 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Married infertile women aged 20 to 39 years (both inclusive), who are diagnosed with tubal infertility, unexplained infertility, grade I-II endometriosis, or spouses diagnosed with male factor infertility, who meet the criteria for IVF and/or ICSI) using fresh or frozen semen from the male spouse or sperm donor
- •BMI 18-25 kg/m2 (both inclusive), body weight range 45-80kg (both inclusive)
- •Subjects must have regular menstrual cycles, specifically defined as ≥25 days, ≤35 days.
- •The serum sex hormone levels during the screening period must be performed in the early follicular phase, and the basal serum follicle-stimulating hormone (FSH) <10 IU/L, LH, estradiol(E2), prolactin(PRL),testosterone(T) levels are within the laboratory normal range, or the investigator considers them as abnormal but not clinically significant
- •The subject is clinically assessed and agree to undergo fresh cycle embryo transfer in the first IVF-ET/ ICSI-Embryo Transfer(ET) cycle, with a maximum of two embryos transferred.
- •Within 1 year before randomization, the presence of bilateral ovaries is clearly visible on transvaginal ultrasonography with no significant abnormalities, and appendages are normal. Both ovaries must be available for oocyte retrieval
- •Subjects must sign the Informed Consent Form (ICF) and be willing and able to abide by the protocol-specified study procedures
排除标准
- •Those who have undergone 2 or more COH of IVF/ICSI-ET before screening, but have not achieved clinical pregnancy.
- •Those with previous IVF or ART failure due to sperm/fertilization problems whose related medical condition has not been improved.
- •Either subjects or their spouses or both of them are known to carry abnormal chromosomal structures, or patients known to have single-gene genetic diseases or serious diseases with genetic susceptibility requiring Preimplantation Genetic Diagnosis(PGD) before embryo transfer.
- •Those with high risk of ovarian hyperstimulation syndrome(OHSS)
- •Those with low ovarian function at screening, with at least one of the following: poor ovarian response in the past; less than 6 antral follicles (AFC) with a diameter of < 10 mm seen on bilateral ovary transvaginal ultrasonography at Day2-3 of menstrual cycle; anti-mullerian hormone(AMH) < 1.1 ng/ml.
- •Subjects who used gonadotropins for ovarian stimulation or drugs that affect ovarian function within 30 days prior to screening.
- •Subjects with abnormal thinprep cytology test(TCT) results that are judged by the investigator as clinically significant and require treatment within 6 months before screening.
- •As judged by the investigator, subjects with clinically significant gynecological diseases at screening
- •Those previously or prior randomization suffering from the cancer of uterine, ovarian, breast or hypothalamus or pituitary gland.
- •Those with a positive serum β-hCG test result at the screening visit or the visit on Day 1 of ovarian stimulation.
- •During COH, LH ≥10 U/L, and the LH level was 2.5 times higher than the baseline value before D0 (inclusive).
研究组 & 干预措施
BG2109 75mg
Experimental
oral, once a day
干预措施: BG2109 (Drug)
BG2109 150mg
Experimental
oral, once a day
干预措施: BG2109 (Drug)
BG2109 200mg
Experimental
oral, once a day
干预措施: BG2109 (Drug)
Cetrorelix
Active Comparator
0.25mg, Subcutaneous injection, once a day
干预措施: Cetrorelix (Drug)
结局指标
主要结局
Suppression rate of premature LH surge from the treatment of investigational medicinal products(IMP) until the day of human chorionic gonadotropin(hCG) injection
时间窗: Through the whole period of administration of IMP，about 5-10 days
LH ≥ 10 IU/L
次要结局
- The number of oocytes obtained on the day of oocyte retrieval(During the surgery of the oocyte retrieval)
- Pharmacodynamics(PD) endpoints(30 minutes before the administration of BG2109 every morning through the whole period of IMP administration，about 5-10 days)
- Ongoing pregnancy rate(At 10 weeks post-embryo transfer)
- Clinical pregnancy rate(On 30-37 days after embryo transfer)
- Adverse drug events(Through study completion, around 45 weeks.)
- Pharmacokinetics(PK) endpoints(On the morning of the Second and Third day of BG2109 administration, and the day of hCG injection(about 5-10days after BG2109 administration))
研究者
研究点 (10)
Loading locations...
相似试验
招募中
3 期
Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.Uterine FibroidsHeavy Menstrual BleedingNCT05620355Bio Genuine (Shanghai) Biotech Co., Ltd.312
招募中
3 期
Efficacy and Safety of BG2109 in Chinese Subjects With EndometriosisModerate to Severe Endometriosis-associated PainEndometriosisNCT05894135Bio Genuine (Shanghai) Biotech Co., Ltd.540
终止
2 期
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT03573505Biogen109
已完成
1 期
Clinical Trial of Comparative Study of GB221 PharmacokineticsMetastatic Breast CancerNCT04175171Genor Biopharma Co., Ltd.32
已完成
1 期
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With HypercholesterolemiaHypercholesterolemiaNCT01979601Novartis Pharmaceuticals74